Head-To-Head Review: Mainz Biomed (NASDAQ:MYNZ) vs. AAR (NYSE:AIR)

AAR (NYSE:AIR) and Mainz Biomed (NASDAQ:MYNZ) are both industrials companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, earnings and dividends.

Profitability

This table compares AAR and Mainz Biomed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AAR	5.67%	12.67%	6.07%
Mainz Biomed	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations for AAR and Mainz Biomed, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AAR	0	2	4	1	2.86
Mainz Biomed	1	1	0	0	1.50

AAR currently has a consensus target price of $135.60, suggesting a potential upside of 0.72%. Given AAR’s stronger consensus rating and higher probable upside, analysts plainly believe AAR is more favorable than Mainz Biomed.

Institutional and Insider Ownership

90.7% of AAR shares are held by institutional investors. 3.1% of AAR shares are held by insiders. Comparatively, 18.2% of Mainz Biomed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares AAR and Mainz Biomed”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AAR	$3.31 billion	1.62	$187.70 million	$4.83	27.87
Mainz Biomed	$659,935.00	18.67	-$21.65 million	($65.60)	-0.02

AAR has higher revenue and earnings than Mainz Biomed. Mainz Biomed is trading at a lower price-to-earnings ratio than AAR, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

AAR has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500.

Summary

AAR beats Mainz Biomed on 13 of the 15 factors compared between the two stocks.

About AAR

AAR Corp. provides products and services to commercial aviation, government, and defense markets worldwide. The Parts Supply segment leases and sells aircraft components and replacement parts. The Repair & Engineering segment provides airframe maintenance services, such as airframe inspection, painting, line maintenance, airframe modification, structural repair, avionics service and installation, exterior and interior refurbishment, and engineering and support services; component repair services comprising maintenance, repair, and overhaul (MRO) services, engine and airframe accessories, and interior refurbishment; and landing gear overhaul services, including repair services on wheels and brakes. This segment also develops specific aircraft components and parts; and designs proprietary designated engineering representative repairs. The Integrated Solutions segment engages in the fleet management and operation of customer-owned aircraft; provision of supply chain logistics services, such as material planning, sourcing, logistics, information and program management, and parts and component repair and overhaul services; and flight hour component inventory and repair services. In addition, the segment provides integrated software solutions comprising Trax, a cloud-based electronic enterprise resource platform, as well as a suite of paperless mobility apps for automating MRO workflows. The Expeditionary Services segment designs, manufactures, and repairs transportation pallets; and containers and shelters for military and humanitarian tactical deployment activities, including armories, supply and parts storage, refrigeration systems, tactical operation centers, briefing rooms, laundry and kitchen facilities, water treatment, and sleeping quarters, as well as engages in provision of engineering, design, and system integration services for specialized command and control systems. AAR Corp. was founded in 1951 and is headquartered in Wood Dale, Illinois.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.